Zimmer Biomet Holdings, Inc. ZBH
Email when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
The news check keeps the assessment current.
General analysis — not personal advice.
Existing position can be maintained pending the Q2 report for clearer direction.
Stable profitability, strong cash flows and raised guidance after the Q3 report support the continued HOLD signal.
Market reacts positively to the earnings beat and raised guidance, with strengthened analyst consensus toward buy.
HOLD is the call. Positive is the market mood. High risk means a lot can go wrong.
Latest change
- 5 Nov 2026 — The report was released on 4 November 2026 and showed stronger-than-expected results driven by growth in hip and technology segments.
The full analysis is open. Follow the company free for the full change history — and email next time the picture changes.
Show all changes (4) — follow the company freeAbout the company
Zimmer Biomet is a leading medical technology company that develops and sells orthopedic implants for knees, hips and extremities as well as robot-assisted surgical solutions such as the ROSA platform. The company holds a strong market position in orthopedics with recurring revenues from implants and surgical tools.
Bull case
Raised full-year guidance and strong growth in technology and robotics segments support the stock.
Bear case
High debt load and weaker performance in certain international markets limit upside.
Why this signal
Stable profitability, strong cash flows and raised guidance after the Q3 report support the continued HOLD signal.
Recent news
Q3 report released 4 November 2026 with net sales of 2.063 billion USD, adjusted EPS of 1.90 USD beating estimates and raised full-year guidance. Shares rose about 13.5 % the same day on heavy volume. Strong growth in hips, S.E.T. and technology segments offsets weaker knee sales.